Skip to main content

Table 3 Change from Baseline in MADRS and Odds Ratio for Response (≥ 50% improvement in MADRS)

From: Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis

PLO

−1.08 [−3.26, 1.10]

−2.29 [−3.47, −1.09]

−4.57 [−5.92, −3.16]

−4.80 [−5.93, − 3.72]

− 1.34 [− 3.29, 0.67]

−4.71 [−6.98, − 2.41]

1.11 [0.80, 1.51]

ARI

− 1.21 [− 3.70, 1.29]

−3.49 [− 6.07, −0.92]

−3.72 [− 6.21, − 1.28]

−0.27 [− 3.24, 2.71]

−3.63 [− 6.78, − 0.50]

1.47 [1.17, 1.82]

1.35 [0.90, 1.95]

CAR

−2.29 [− 4.09, − 0.46]

−2.52 [− 4.11, − 0.92]

0.94 [− 1.34, 3.27]

−2.42 [− 5.01, 0.14]

1.56 [1.20, 2.01]

1.44 [0.94, 2.14]

1.08 [0.76, 1.51]

OLA

−0.23 [−2.05, 1.53]

3.23 [0.83, 5.66]

− 0.13 [− 2.82, 2.50]

2.09 [1.74, 2.49]

1.92 [1.32, 2.71]

1.44 [1.08, 1.91]

1.36 [0.98, 1.84]

QUE

3.46 [1.24, 5.76]

0.10 [−2.44, 2.61]

1.07 [0.77, 1.46]

0.99 [0.61, 1.50]

0.74 [0.50, 1.08]

0.70 [0.45, 1.03]

0.52 [0.35, 0.74]

ZIP

−3.36 [− 6.38, − 0.39]

2.58 [1.67, 3.81]

2.38 [1.38, 3.85]

1.78 [1.08, 2.77]

1.68 [0.99, 2.65]

1.25 [0.78, 1.90]

2.47 [1.41, 3.98]

LUR

  1. Note: MADRS results are on the top-right and response results are on the bottom-left. Results give the mean change and odds ratio [95% credible interval]. In the top-right comparisons, the row treatment is the reference category. In the bottom-left, the column treatment is the reference category. Response was defined as ≥50% improvement in MADRS
  2. Abbreviations: MADRS Montgomery–Åsberg Depression Rating Scale, PLO Placebo, ARI Aripiprazole, CAR Cariprazine, LUR Lurasidone, OLA Olanzapine, QUE Quetiapine, ZIP Ziprasidone